{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-055334","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.739921+00:00","generated_at":"2026-05-19T02:55:01.302086+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program","bullets":["Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.","He will lead development of NDV-01, a gemcitabine/docetaxel sustained release formulation for NMIBC.","Company presented positive Phase 2 data at AUA 2025; Phase 3 trial expected to begin H1 2026.","Dr. Pruthi brings over 25 years experience in urologic oncology, including roles at enGene and J&J."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-055334","json":"https://secwatch.observer/filing/0001213900-25-055334.json","markdown":"https://secwatch.observer/filing/0001213900-25-055334.md","text":"https://secwatch.observer/filing/0001213900-25-055334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/0001213900-25-055334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/ea0246111-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:55:01.302086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}